US Stock MarketDetailed Quotes

XTL Biopharmaceuticals (XTLB)

Watchlist
  • 2.370
  • -0.110-4.43%
Close Apr 10 16:00 ET
  • 2.370
  • 0.0000.00%
Post 20:01 ET
5.61MMarket Cap-0.66P/E (TTM)

XTL Biopharmaceuticals (XTLB) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
451K
289K
162K
0
0
0
0
0
0
0
Operating revenue
--451K
--289K
--162K
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
448K
332K
116K
0
0
Gross profit
3K
-43K
46K
0
0
Operating expense
184.31%2.18M
284.50%769K
436.42%810K
158.28%421K
-30.28%175K
-13.07%765K
-11.11%200K
-25.98%151K
-19.31%163K
0.80%251K
Selling and administrative expenses
178.75%2.05M
263.92%706K
421.38%756K
164.33%415K
-28.99%169K
-13.65%734K
-11.42%194K
-27.86%145K
-16.04%157K
-2.06%238K
-Selling and marketing expense
--178K
---106K
--284K
----
----
--0
--0
----
----
----
-General and administrative expense
154.50%1.87M
318.56%812K
225.52%472K
164.33%415K
-28.99%169K
-13.65%734K
-11.42%194K
-27.86%145K
-16.04%157K
-2.06%238K
Research and development costs
216.13%98K
433.33%32K
800.00%54K
0.00%6K
-53.85%6K
3.33%31K
0.00%6K
100.00%6K
-60.00%6K
116.67%13K
Depreciation amortization depletion
--31K
----
----
----
----
--0
----
----
----
----
-Depreciation and amortization
--31K
----
----
----
----
--0
----
----
----
----
Operating profit
-183.92%-2.17M
-306.00%-812K
-405.96%-764K
-158.28%-421K
30.28%-175K
13.07%-765K
11.11%-200K
25.98%-151K
19.31%-163K
-0.80%-251K
Net non-operating interest income expense
-240.54%-52K
-58.70%38K
-321.05%-80K
82.61%-4K
53.85%-6K
48.00%37K
240.74%92K
-290.00%-19K
-283.33%-23K
-116.67%-13K
Non-operating interest income
-17.07%34K
-81.82%2K
44.44%13K
0.00%9K
-16.67%10K
13.89%41K
-31.25%11K
-25.00%9K
80.00%9K
300.00%12K
Non-operating interest expense
--28K
-10.59%-94K
232.14%93K
-59.38%13K
-36.00%16K
--0
-286.36%-85K
1,300.00%28K
190.91%32K
177.78%25K
Total other finance cost
1,350.00%58K
----
----
----
----
-63.64%4K
----
----
----
----
Other net income (expense)
201.23%1.07M
321.02%389K
746.67%291K
-56.74%-279K
201.68%666K
-113.79%-1.05M
68.00%-176K
92.82%-45K
-131.17%-178K
-186.07%-655K
Gain on sale of security
201.23%1.07M
321.02%389K
746.67%291K
-56.74%-279K
201.68%666K
-113.79%-1.05M
68.00%-176K
92.82%-45K
-131.17%-178K
-186.07%-655K
Income before tax
35.07%-1.16M
-35.56%-385K
-157.21%-553K
-93.41%-704K
152.77%485K
-32.20%-1.78M
62.03%-284K
73.81%-215K
-27.72%-364K
-281.62%-919K
Income tax
-130K
0
Net income
42.37%-1.03M
10.21%-255K
-157.21%-553K
-93.41%-704K
152.77%485K
-32.20%-1.78M
62.03%-284K
73.81%-215K
-27.72%-364K
-281.62%-919K
Net income continuous Operations
42.37%-1.03M
10.21%-255K
-157.21%-553K
-93.41%-704K
152.77%485K
-32.20%-1.78M
62.03%-284K
73.81%-215K
-27.72%-364K
-281.62%-919K
Minority interest income
Net income attributable to the parent company
42.37%-1.03M
10.21%-255K
-157.21%-553K
-93.41%-704K
152.77%485K
-32.20%-1.78M
62.03%-284K
73.81%-215K
-27.72%-364K
-281.62%-919K
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
42.37%-1.03M
10.21%-255K
-157.21%-553K
-93.41%-704K
152.77%485K
-32.20%-1.78M
62.03%-284K
73.81%-215K
-27.72%-364K
-281.62%-919K
Basic earnings per share
33.33%-0.8
-0.4
66.67%-0.4
-159.29%-0.4
159.29%0.4
-50.00%-1.2
0
-113.44%-1.2
268.65%0.6746
-268.65%-0.6746
Diluted earnings per share
0.00%-1.2
-0.4
33.33%-0.8
-159.29%-0.4
159.29%0.4
-50.00%-1.2
0
-113.44%-1.2
268.65%0.6746
-281.62%-0.6746
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 451K289K162K0000000
Operating revenue --451K--289K--162K--0--0--0--0--0--0--0
Cost of revenue 448K332K116K00
Gross profit 3K-43K46K00
Operating expense 184.31%2.18M284.50%769K436.42%810K158.28%421K-30.28%175K-13.07%765K-11.11%200K-25.98%151K-19.31%163K0.80%251K
Selling and administrative expenses 178.75%2.05M263.92%706K421.38%756K164.33%415K-28.99%169K-13.65%734K-11.42%194K-27.86%145K-16.04%157K-2.06%238K
-Selling and marketing expense --178K---106K--284K----------0--0------------
-General and administrative expense 154.50%1.87M318.56%812K225.52%472K164.33%415K-28.99%169K-13.65%734K-11.42%194K-27.86%145K-16.04%157K-2.06%238K
Research and development costs 216.13%98K433.33%32K800.00%54K0.00%6K-53.85%6K3.33%31K0.00%6K100.00%6K-60.00%6K116.67%13K
Depreciation amortization depletion --31K------------------0----------------
-Depreciation and amortization --31K------------------0----------------
Operating profit -183.92%-2.17M-306.00%-812K-405.96%-764K-158.28%-421K30.28%-175K13.07%-765K11.11%-200K25.98%-151K19.31%-163K-0.80%-251K
Net non-operating interest income expense -240.54%-52K-58.70%38K-321.05%-80K82.61%-4K53.85%-6K48.00%37K240.74%92K-290.00%-19K-283.33%-23K-116.67%-13K
Non-operating interest income -17.07%34K-81.82%2K44.44%13K0.00%9K-16.67%10K13.89%41K-31.25%11K-25.00%9K80.00%9K300.00%12K
Non-operating interest expense --28K-10.59%-94K232.14%93K-59.38%13K-36.00%16K--0-286.36%-85K1,300.00%28K190.91%32K177.78%25K
Total other finance cost 1,350.00%58K-----------------63.64%4K----------------
Other net income (expense) 201.23%1.07M321.02%389K746.67%291K-56.74%-279K201.68%666K-113.79%-1.05M68.00%-176K92.82%-45K-131.17%-178K-186.07%-655K
Gain on sale of security 201.23%1.07M321.02%389K746.67%291K-56.74%-279K201.68%666K-113.79%-1.05M68.00%-176K92.82%-45K-131.17%-178K-186.07%-655K
Income before tax 35.07%-1.16M-35.56%-385K-157.21%-553K-93.41%-704K152.77%485K-32.20%-1.78M62.03%-284K73.81%-215K-27.72%-364K-281.62%-919K
Income tax -130K0
Net income 42.37%-1.03M10.21%-255K-157.21%-553K-93.41%-704K152.77%485K-32.20%-1.78M62.03%-284K73.81%-215K-27.72%-364K-281.62%-919K
Net income continuous Operations 42.37%-1.03M10.21%-255K-157.21%-553K-93.41%-704K152.77%485K-32.20%-1.78M62.03%-284K73.81%-215K-27.72%-364K-281.62%-919K
Minority interest income
Net income attributable to the parent company 42.37%-1.03M10.21%-255K-157.21%-553K-93.41%-704K152.77%485K-32.20%-1.78M62.03%-284K73.81%-215K-27.72%-364K-281.62%-919K
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 42.37%-1.03M10.21%-255K-157.21%-553K-93.41%-704K152.77%485K-32.20%-1.78M62.03%-284K73.81%-215K-27.72%-364K-281.62%-919K
Basic earnings per share 33.33%-0.8-0.466.67%-0.4-159.29%-0.4159.29%0.4-50.00%-1.20-113.44%-1.2268.65%0.6746-268.65%-0.6746
Diluted earnings per share 0.00%-1.2-0.433.33%-0.8-159.29%-0.4159.29%0.4-50.00%-1.20-113.44%-1.2268.65%0.6746-281.62%-0.6746
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion--------
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 12 local time, U.S. Vice President Vance stated that negotiations between the United States and Iran failed to reach an agreement, Show More